Feature | ASTRO | September 23, 2019

Top Radiation Oncology Research and Clinical Trials at ASTRO 2019

ASTRO highlights top-rated abstract presentations at its annual meeting

An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart. #ASTRO19 #ASTRO2019 #ASTRO

An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart.

August 29, 2019 — The American Society for Radiation Oncology (ASTRO) announced the top-rated studies being highlighted at the 2019 ASTRO Annual Meeting, Sept. 15 - 18 in Chicago. These presentations are being highlighted with press conferences.

Presentations Sunday, Sept. 15:

   • Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial, presented by Daniel Spratt, University of Michigan Rogel Cancer Center (Abstract LBA-1)

   • Primary Outcomes of a Phase II Randomized Trial of Observation versus Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (ORIOLE), presented by  Ryan Phillips, Johns Hopkins Kimmel Cancer Center (Abstract LBA-3)

   • Cosmetic Outcome from Post Lumpectomy Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 Phase III Clinical Trial, presented by Julia White, The Ohio State University Comprehensive Cancer Center (Abstract 5)

   • Longer Term Results from a Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia (ENCORE-VT)," presented by  Clifford Robinson, Washington University School of Medicine in St. Louis (Abstract LBA-4)

Presentations Monday, Sept. 16:

   • Final Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), presented by Allison Campbell, Yale Cancer Center (Abstract 74)

   • Patterns of Disease Progression with Durvalumab in Stage III NSCLC (PACIFIC), presented by Andreas Rimner, Memorial Sloan Kettering Cancer Center (Abstract LBA-6)

   • Applying a Machine Learning Approach to Predict Acute Radiation Toxicities for Head and Neck Cancer Patients, presented by Jay P. Reddy, The University of Texas MD Anderson Cancer Center (Abstract 141)

   • The Impact of the Closure of Women’s Health Clinics on Cervical Cancer in the United States, presented by Amar Srivastava, Washington University School of Medicine in St. Louis (Abstract 202)

The 2019 ASTRO Annual Meeting is expected to attract more than 10,000 oncologists, clinicians, researchers and other healthcare professionals from across the globe. Throughout the four-day meeting, researchers will present peer-reviewed abstracts on advances in clinical care for cancer patients, while panels and interactive case discussions featuring leading experts will underscore the meeting’s theme, “Innovate, Collaborate: Transform.”

 

ASTRO 2019 Video Interviews:

VIDEO: Artificial Intelligence Driven Adaptive Radiotherapy System Begins Treating Patients — Interview with David Sjostrom, Ph.D.

VIDEO: Clinical and Physics Aspects of Re-irradiation of Previously Treated Radiotherapy Tumor Sites — Interview with Kristin Higgins, M.D.

VIDEO: Cardiac Radiotherapy Ablation to Treat Ventricular Tachycardia — Interview with Clifford Robinson, M.D.

VIDEO: Understanding the Radiation Oncology Alternative Payment Model — Interview with Anne Hubbard, MBA, ASTRO

VIDEO: Preserving Neurocognitive Function During Whole-Brain Radiotherapy — Interview with Vinai Gondi, M.D.

VIDEO: Palliative Radiation Oncology For Patients Who Need Symptom Relief — Interview with Candice Johnstone, M.D.

VIDEO: Use of Hydrogel to Reduce Rectal Toxicity for Prostate Radiotherapy — Interview with Bill Hartsell, M.D.

VIDEO: Integration of Advanced Practice Providers in Radiation Oncology — Interview with Lorraine Drapek, DNP

 

Late-breaking Radiation Therapy Clinical Trials at ASTRO 2018

Find more news and video from ASTRO

 

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 New studies use SIRD model to forecast COVID-19 spread; examine patient CT scans to correlate clinical features with mortality

Fig 1. A sample scoring on CT images of a 63-year-old woman from mortality group demonstrated a total score of 63. It was calculated as: for upper zone (A), 3 (consolidation) × 3 (50–75% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) ×1 (< 25% distribution) × 2 (both right and left lungs); for middle zone (B), 3 (consolidation) × 2 (25–50% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) × 2 (25–50% distribution) × 2 (both right and left lungs); for lower zone (C), 3 (consolidation) × (2 (25–50% distribution of the right lung) + 3 (50–75% distribution of the left lung)) + 2 (ground glass opacity) × (2 (25–50% distribution of the right lung) + 1 (< 25% distribution of the left lung)) Yuan et al, 2020 (CC BY 4.0)

News | Coronavirus (COVID-19) | April 01, 2020
April 1, 2020 — A new study, ...
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...